Azitra, Inc. Announces Reverse Stock Split
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced a 1-for-6.66 reverse stock split effective August 21, 2025. The company's common stock will continue trading under the symbol "AZTR" on the NYSE American with a new CUSIP number 05479L302.
The reverse split will reduce Azitra's outstanding shares from 23,476,354 to approximately 3,524,978. Stockholders will receive cash in lieu of fractional shares, calculated based on the average closing prices for the five trading days before the split. The split will proportionally adjust equity awards and warrants, including their exercise prices.
["Will help maintain NYSE American listing requirements", "No change to stockholder's percentage ownership in the company", "Stockholders automatically receive cash for fractional shares"]Azitra (NYSE American: AZTR), società biofarmaceutica in fase clinica specializzata in dermatologia di precisione, ha annunciato un raggruppamento azionario inverso 1 per 6,66 con efficacia il 21 agosto 2025. Le azioni ordinarie della società continueranno a negoziare con il simbolo "AZTR" sulla NYSE American con un nuovo numero CUSIP 05479L302.
Il raggruppamento ridurrà il numero di azioni in circolazione di Azitra da 23,476,354 a circa 3,524,978. Gli azionisti riceveranno denaro in luogo di azioni frazionarie, calcolato in base al prezzo medio di chiusura dei cinque giorni di negoziazione precedenti al raggruppamento. L'operazione adeguerà proporzionalmente i premi azionari e i warrant, inclusi i relativi prezzi d'esercizio.
- Aiuterà a mantenere i requisiti di quotazione della NYSE American
- Non cambia la percentuale di partecipazione degli azionisti nella società
- Gli azionisti riceveranno automaticamente denaro per le azioni frazionarie
Azitra (NYSE American: AZTR), una compañía biofarmacéutica en fase clínica especializada en dermatología de precisión, ha anunciado una consolidación inversa de acciones 1 por 6,66 con vigencia el 21 de agosto de 2025. Las acciones ordinarias de la compañía seguirán cotizando bajo el símbolo "AZTR" en la NYSE American con un nuevo número CUSIP 05479L302.
La consolidación reducirá las acciones en circulación de Azitra de 23,476,354 a aproximadamente 3,524,978. Los accionistas recibirán efectivo en lugar de acciones fraccionarias, calculado en base a los precios de cierre promedio de los cinco días hábiles anteriores a la consolidación. La operación ajustará proporcionalmente las concesiones de capital y los warrants, incluidos sus precios de ejercicio.
- Ayudará a mantener los requisitos de cotización de la NYSE American
- No cambia el porcentaje de participación de los accionistas en la compañía
- Los accionistas recibirán automáticamente efectivo por las acciones fraccionarias
Azitra (NYSE American: AZTR)는 정밀 피부과학을 전문으로 하는 임상 단계의 바이오제약회사로, 1대6.66 역병합을 2025년 8월 21일부로 시행한다고 발표했습니다. 회사의 보통주는 NYSE American에서 심볼 "AZTR"로 계속 거래되며 새로운 CUSIP 번호는 05479L302입니다.
이번 역병합으로 Azitra의 유통 주식 수는 23,476,354주에서 약 3,524,978주로 줄어듭니다. 주주들은 병합 후 발생하는 소수주에 대해 병합 직전 5거래일의 종가 평균을 기준으로 현금으로 지급받게 됩니다. 또한 이 병합은 주식 보상과 워런트 및 해당 행사가를 비례적으로 조정합니다.
- NYSE American 상장 요건을 유지하는 데 도움이 됩니다
- 주주들의 지분 비율에는 변화가 없습니다
- 소수주에 대해서는 주주들에게 자동으로 현금이 지급됩니다
Azitra (NYSE American: AZTR), une société biopharmaceutique en phase clinique spécialisée en dermatologie de précision, a annoncé un regroupement d'actions au ratio 1 pour 6,66 prenant effet le 21 août 2025. Les actions ordinaires de la société continueront d'être négociées sous le symbole "AZTR" sur la NYSE American avec un nouveau numéro CUSIP 05479L302.
Le regroupement réduira le nombre d'actions en circulation d'Azitra de 23,476,354 à environ 3,524,978. Les actionnaires recevront de l'argent en lieu et place des actions fractionnaires, calculé sur la base des cours de clôture moyens des cinq jours de bourse précédant le regroupement. L'opération ajustera proportionnellement les attributions d'actions et les warrants, y compris leurs prix d'exercice.
- Aidera à maintenir les conditions de cotation sur la NYSE American
- Ne modifie pas le pourcentage de participation des actionnaires dans la société
- Les actionnaires recevront automatiquement de l'argent pour les actions fractionnaires
Azitra (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in klinischer Phase mit Schwerpunkt auf Präzisionsdermatologie, hat eine Aktienzusammenlegung im Verhältnis 1 zu 6,66 angekündigt, die am 21. August 2025 wirksam wird. Die Stammaktien des Unternehmens werden weiterhin unter dem Symbol "AZTR" an der NYSE American gehandelt und erhalten eine neue CUSIP-Nummer 05479L302.
Die Zusammenlegung reduziert die ausstehenden Aktien von Azitra von 23,476,354 auf etwa 3,524,978. Aktionäre erhalten für Bruchstücke Bargeld, berechnet auf Grundlage des durchschnittlichen Schlusskurses der fünf Handelstage vor der Zusammenlegung. Die Anpassung wird auch Aktienvergütungen und Warrants sowie deren Ausübungspreise anteilig anpassen.
- Hilft, die Anforderungen für die Notierung an der NYSE American aufrechtzuerhalten
- Ändert nicht den prozentualen Anteil der Aktionäre am Unternehmen
- Aktionäre erhalten automatisch Bargeld für Bruchstücke
- None.
- Significant reduction in total outstanding shares could impact stock liquidity
- Additional administrative costs for processing fractional shares
- May indicate company's struggle to maintain minimum share price requirements
Insights
Azitra's 1:6.66 reverse split aims to boost share price but signals potential financial concerns without addressing fundamental business issues.
Azitra's announcement of a 1-for-6.66 reverse stock split is a significant financial engineering move that warrants careful investor attention. This maneuver will dramatically reduce the company's outstanding shares from 23,476,354 to approximately 3,524,978, with trading on the split-adjusted basis beginning August 21, 2025.
The unusually precise split ratio of 1:6.66 is noteworthy - most companies opt for cleaner ratios like 1:5 or 1:10. This specific ratio suggests Azitra is precisely targeting a particular post-split share price, likely to meet the NYSE American's continued listing requirements which mandate a minimum share price (typically $1.00).
While reverse splits are technically neutral transactions that don't change a company's underlying value, they historically send concerning signals to the market. Companies typically implement reverse splits after prolonged share price declines, and research shows that stocks undergoing reverse splits often continue underperforming the market post-split.
The timing is also telling - Azitra obtained shareholder approval back in February but waited six months to implement it. This delay suggests management may have been hoping for organic share price recovery that never materialized, forcing their hand with this financial engineering solution. For a clinical-stage biopharmaceutical company focused on precision dermatology, this split addresses share price symptoms rather than potential underlying issues with clinical progress or cash runway.
Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025
At a special meeting of stockholders held on February 20, 2025, the Company's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of the Company's common stock through an amendment to its Second Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-7, with such ratio to be determined by the Company's Board of Directors. On August 7, 2025, the Board of Directors of Azitra approved the final split ratio of 1-for-6.66 and the effective date of August 21, 2025.
At the effective time of the reverse stock split, every 6.66 shares of the Company's issued common stock will be converted automatically into one issued share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-6.66 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares of common stock will be issued in connection with the reverse split. Stockholders of record who otherwise would be entitled to receive fractional shares, will be entitled to receive cash (without interest) in lieu of fractional shares, equal to such fraction multiplied by the average of the closing sales prices of the common stock on the NYSE American during regular trading hours for the five consecutive trading days immediately preceding the effective date of the reverse split (with such average closing sales prices being adjusted to give effect to the reverse split).
The reverse stock split will reduce the number of issued shares of the Company's common stock from 23,476,354 shares to approximately 3,524,978 shares. Proportional adjustments will be made to the number of shares of the Company's common stock issuable upon exercise or conversion of the Company's equity awards and warrants, as well as the applicable exercise price. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company's transfer agent, VStock Transfer Company, at action@vstocktransfer.com.
Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on January 14, 2025, which is available free of charge at the SEC's website, www.sec.gov, and on the Company's website at https://azitrainc.com/.
About Azitra, Inc.
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adults with Netherton syndrome. ATR-04, Azitra's additional clinical program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated skin toxicity; a Phase 1/2 clinical trial has been initiated for this program. Azitra has received Fast Track designation from the FDA for this program to treat EGFRi associated rash, which impacts approximately 150,000 people in
Contacts
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-announces-reverse-stock-split-302526802.html
SOURCE Azitra, Inc.
FAQ
When will Azitra's (AZTR) reverse stock split take effect?
What is the ratio of Azitra's (AZTR) reverse stock split?
How many shares will Azitra (AZTR) have after the reverse split?
Do Azitra (AZTR) shareholders need to take any action for the reverse split?
What happens to fractional shares in Azitra's (AZTR) reverse split?
